Point-of-Care Troponin Product Meets Guidelines for Heart Attack Detection
By LabMedica International staff writers Posted on 19 Feb 2014 |
A point-of-care troponin product is capable of meeting all of the guidelines stipulated by the world's leading cardiac organizations for detection.
Trinity Biotech (Wicklow, Ireland) has announced European approval of a guideline compliant, point-of-care, high sensitivity Troponin I product. That is, the troponin I product has received the CE marking for its Meritas, high sensitivity Troponin I (hsTnI) product. Troponin is the leading marker used in the detection of heart attacks or myocardial infarctions (MI).
The worldwide segment for Cardiac Troponin testing is estimated to be USD 1.2 billion, growing at a rate of 12% per annum. Of this market, approximately USD 350 million represents point-of-care testing carried out in the Emergency Room (ER) with the remainder being laboratory based testing.
This test delivers sensitivity and precision at the point-of-care, which allows doctors to evaluate whether or not patients are having a heart attack within a short time of admission.
The future plans of Trinity Biotech will include an immediate launch of its Troponin product for sale in Europe and as well as commencement of US trials with the aim of receiving the US Food and Drug Administration (Silver Spring, MD, USA) approval.
Related Links:
Trinity Biotech
US Food and Drug Administration
Trinity Biotech (Wicklow, Ireland) has announced European approval of a guideline compliant, point-of-care, high sensitivity Troponin I product. That is, the troponin I product has received the CE marking for its Meritas, high sensitivity Troponin I (hsTnI) product. Troponin is the leading marker used in the detection of heart attacks or myocardial infarctions (MI).
The worldwide segment for Cardiac Troponin testing is estimated to be USD 1.2 billion, growing at a rate of 12% per annum. Of this market, approximately USD 350 million represents point-of-care testing carried out in the Emergency Room (ER) with the remainder being laboratory based testing.
This test delivers sensitivity and precision at the point-of-care, which allows doctors to evaluate whether or not patients are having a heart attack within a short time of admission.
The future plans of Trinity Biotech will include an immediate launch of its Troponin product for sale in Europe and as well as commencement of US trials with the aim of receiving the US Food and Drug Administration (Silver Spring, MD, USA) approval.
Related Links:
Trinity Biotech
US Food and Drug Administration
Latest Technology News
- New Diagnostic System Achieves PCR Testing Accuracy
- DNA Biosensor Enables Early Diagnosis of Cervical Cancer
- Self-Heating Microfluidic Devices Can Detect Diseases in Tiny Blood or Fluid Samples
- Breakthrough in Diagnostic Technology Could Make On-The-Spot Testing Widely Accessible
- First of Its Kind Technology Detects Glucose in Human Saliva
- Electrochemical Device Identifies People at Higher Risk for Osteoporosis Using Single Blood Drop
- Novel Noninvasive Test Detects Malaria Infection without Blood Sample
- Portable Optofluidic Sensing Devices Could Simultaneously Perform Variety of Medical Tests
- Point-of-Care Software Solution Helps Manage Disparate POCT Scenarios across Patient Testing Locations
- Electronic Biosensor Detects Biomarkers in Whole Blood Samples without Addition of Reagents
- Breakthrough Test Detects Biological Markers Related to Wider Variety of Cancers
- Rapid POC Sensing Kit to Determine Gut Health from Blood Serum and Stool Samples
- Device Converts Smartphone into Fluorescence Microscope for Just USD 50
- Wi-Fi Enabled Handheld Tube Reader Designed for Easy Portability